Navigation Links
LifeCare Holdings, Inc. Announces Third Quarter Results
Date:11/14/2007

at are effective for discharges occurring on or after July 1, 2007. The final rule was amended on June 29, 2007 by revising the high cost outlier threshold. CMS estimates these changes will reduce overall payments to LTAC hospitals by 1.2% in the first year of implementation. These changes include: (a) a 0.71% increase to the standard federal payment rate from $38,086 to $38,356; (b) revisions to payment methodologies impacting short-stay outliers; (c) adjustments to the wage index component of the federal payment; (d) an extension of the policy known as the "25 Percent Rule" to all LTAC hospitals, including those previously exempted due to a "grandfather status," with a three year phase-in; and (e) an increase in the high-cost outlier fixed-loss threshold amount from $14,887 to $20,738. The proposed short-stay outlier revisions include the creation of a new payment category for discharged cases having lengths of stay less than or equal to the geometric mean length of stay for patients with the same diagnosis in short-term acute care hospitals. Payment for these cases would be similar to that received by a short-term acute care hospital for the same diagnosis.

CMS also states that the annual update to the DRG classifications and relative weights will be made in a budget neutral manner, effective October 1, 2007. As such, the estimated aggregate industry LTAC PPS payments would be unaffected by the annual recalibration of DRG payment weights.

While we believe that the new policy will reduce our Medicare reimbursement, we will attempt to mitigate the effect of these recent regulatory changes. There can be no guarantee that such efforts will be successful.

CMS Changes to DRG Weighting for Fiscal 2008

On August 1, 2007, CMS issued final inpatient prospective payment system (IPPS) regulations for fiscal year 2008. These regulations establish a new Medicare severity-based patient classification system for fiscal year 2008, called the Medicare-Sever
'/>"/>

SOURCE LifeCare Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine news :

1. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
2. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
3. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
4. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
5. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
6. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
7. China Shenghuo Pharmaceutical Holdings, Inc. Opens Showcase 12Ways(R) Chinese Herbal Beauty Salon in October
8. NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results
9. Duane Reade Holdings, Inc. to Report Third Quarter 2007 Financial Results
10. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
11. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...team develops device giving patients freedom of mo...DAY, July 26 (HealthDay News) -- An automated arti...e day be to dialysis patients what the insulin pum...rable artificial kidney (AWAK) works better than c...current issue of Clinical and Experimental Nephro...
(Date:7/25/2008)...AKE SUCCESS, N.Y., July 25 /PRNewswire-USNewswire/...as Chief Quality Officer and Vice President,of Str...monwealth Fund, a,national foundation committed to...e directed the foundation,s Program on Health Care...p://www.newscom.com/cgi-bin/prnh/20080725/DC28791L...
(Date:7/25/2008)...red immune response after antiretroviral therapy m... July 25 (HealthDay News) -- A new study challenge...(HCV) impairs the immune system,s ability to resto...ly active antiretroviral therapy (HAART). , Fro...ers are also infected with HCV. Intravenous drug u...
(Date:7/25/2008)...he Authority offers patients consumers tips and en...ient safety, HARRISBURG, Pa., July 25 /PRNewswire...thority today supports "National Patient Safety Da...s and their families to,participate fully in their...thing they can about their surgery or illness., "...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3
...ngton, in Seattle, a group of engineers has recent... latest creation: a surgical robot// to deploy in ... a remote control console. Military groups all ov... in remote surgery. On the battlefield, medical re...
...Children's Research Hospital have discovered that ...duction of a molecule that is key to the ability//...s to break down toxins, and of cells to extract en...estigators showed that ABCB6 is lodged within the ...
...ide rates among younger and older Americans have b...ling news: No one really knows why// . Those are ...t the University of South Carolina and released Th...tober issue of the American Journal of Public Heal...
...lty members performing microsurgery in Tanzania fr...om, or health care experts// in Vietnam presenting...thered in the Hopkins outpatient center. These are... Internet communication system that will be used f...
Other Medicine News:Health News:Doc at a Distance 2Health News:ABCB6 Is Key to Production of Heme in Hemoglobin 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 3Health News:High-Speed Internet2 Link Revolutionizes Global Medical Education 2
(Date:7/24/2008)... /PRNewswire-USNewswire/ -- Headlines claiming "so...e story. The small scale,preliminary study that D...duction, is based on recollected intake of soyfood...This study is confounded by many,issues, thus I fe...of,caution," warned Dr. Tammy Hedlund, a researche...
(Date:7/24/2008)...rance, July 24 /- NicOx S.A...ne results from the 52-week,open label safety exte...of,the 301 phase 3 study for naproxcinod. The resu...icacy was maintained for the one-year duration of,...essment scale. In,addition, the results showed tha...
(Date:7/23/2008)... /PRNewswire-USNewswire/ -- The following was,rele... Conyers, Ranking Member Smith, and Members of the...fy today., Since I appeared before this Committee...acquainted with the talented and dedicated profess... they do, and I have come to,appreciate that much ...
(Date:7/23/2008)...RNewswire-FirstCall/ -- Dendreon Corporation,(Nasd...dependent Data,Monitoring Committee (IDMC) to revi... survival relating to the Company,s Phase 3 IMPACT...ent, also known as D9902B) clinical trial,of PROVE...nvestigational,active cellular immunotherapy for t...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Steps toward Stopping Autoimmune Disease 1967 1Steps toward Stopping Autoimmune Disease 1967 2CeloNova BioSciences Announces Positive Results from European Study of Embozene 28TM 29 Microspheres for Treatment of Uterine Fibroids 1229 1CeloNova BioSciences Announces Positive Results from European Study of Embozene 28TM 29 Microspheres for Treatment of Uterine Fibroids 1229 2Students Pursuing Health Care Careers Receive 2424 000 in Scholarships From National Hispanic Health Foundation 9799 1Students Pursuing Health Care Careers Receive 2424 000 in Scholarships From National Hispanic Health Foundation 9799 2Solutions for Parents Who Need Cold Remedies for Their Children 9795 1Solutions for Parents Who Need Cold Remedies for Their Children 9795 2
...EGO, May 22, 2007 /PRNewswire/ -- A new study pres...iddle-of-the-night,balance, mobility or memory per...o placebo. This study also demonstrated, as in,pre... did have,impaired performances on these measures,...e-blind, placebo-controlled trial were,presented i...
... Release of Data for New Combination , , , , , P...cium channel blocker,amlodipine besylate with the ... produced significant mean reductions in,seated sy...th,hypertension, according to data presented at th...Second Annual Scientific Meeting and,Exposition (A...
Other Medicine Technology:New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 2New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 3New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 4Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 2Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 3Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 4
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments.
Liquichek Qualitative Urine Toxicology Control is a liquid control designed for use with qualitative rapid urine drug screen panels, including Point of Care (POC) Drugs of Abuse (DOA) test kits like
Liquichek Sedimentation Rate Control is a bilevel human whole blood based control designed to monitor both manual and automated methods for measuring erythrocyte sedimentation rates.
Liquichek Hematology-16 Control is specifically designed for use on most hematology analyzers that measure up to 16 parameters and 3-part white blood cell differentials. This trilevel control can be
Medicine Products: